Related Experiment Video
Updated: Apr 8, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.4K
Liraglutide for Type 2 diabetes and obesity: a 2015 update
Eva Winning Iepsen1, Signe Sørensen Torekov, Jens Juul Holst
1The NNF Center for Basic Metabolic Research and, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen N, Denmark.
Expert Review of Cardiovascular Therapy
|June 25, 2015
Summary
Liraglutide effectively treats Type 2 diabetes and promotes weight loss by increasing insulin secretion and reducing appetite. It also shows potential in preventing prediabetes and bone loss.
Area of Science:
- Pharmacology and Endocrinology
- Metabolic Diseases
Background:
- Liraglutide is approved for Type 2 diabetes (T2DM) and chronic weight management.
- It enhances glucose-dependent insulin secretion and decreases glucagon secretion.
Purpose of the Study:
- To review clinical trials of liraglutide in T2DM and obesity.
- To explore the pharmacological mechanisms underlying liraglutide's effects.
Main Methods:
- Review of major clinical trials on liraglutide efficacy.
- Analysis of pharmacological data on liraglutide's mechanism of action.
Main Results:
- Liraglutide promotes weight loss by inhibiting appetite and inducing satiety.
- Potential benefits include protection against prediabetes and prevention of bone loss.
Conclusions:
- Liraglutide is a valuable therapeutic agent for T2DM and obesity.
- Further research into its mechanisms may reveal additional health benefits.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
974
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
974
01:06Oral Hypoglycemic Agents: Glinides
977
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
977
01:22Diabetes Mellitus: Type 2 and Gestational
5.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.6K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
893
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
893